Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Wed, 25.06.2025
Evotec SE
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK
The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr [ … ]
Tue, 03.06.2025
Evotec SE
All agenda items adopted
Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook
46.45% of the registered share capital represented
Hamburg, Germany, 03 June 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that [ … ]
Wed, 07.05.2025
Evotec SE
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.
The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
[ … ]
Tue, 06.05.2025
Evotec SE
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just – Evotec Biologics with continuing growth momentum
Strong progress in strategic protein degradation partnership with Bristol Myers Squibb
Strategy building on technology and science leadership: Focus on high-growth, high-value segme [ … ]
Tue, 29.04.2025
Evotec SE
Hamburg, Germany, 29 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call [ … ]
Thu, 24.04.2025
Evotec SE
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 24 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt [ … ]
Thu, 17.04.2025
Evotec SE
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth
Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence
Strong Q4 2024 revenue and EBITDA results in spite of ch [ … ]
Thu, 10.04.2025
Evotec SE
Hamburg, Germany, 10 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025.
The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The confe [ … ]
Tue, 04.03.2025
Evotec SE
Ongoing strategic partnership advances joint pipeline in neurodegeneration research
Evotec receives a $20 million payment to further progress research
Hamburg, Germany, 04 March 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced another major accomplishment in its long [ … ]
Wed, 26.02.2025
Evotec SE
Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025
Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025
Hamburg, Germany, 26 February 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Financia [ … ]